Synthesis, DNA binding, topoisomerases inhibition and cytotoxic properties of 4-arylcarboxamidopyrrolo-2-carboxyanilides

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 6, 2000, Pages 553-557

  Dudouit, Fabienne ^a   Goossens, Jean François ^a   Houssin, Raymond ^a   Hénichart, Jean Pierre ^a   Colson, Pierre ^b   Houssier, Claude ^b   Gelus, Nathalie ^c   Bailly, Christian ^c  

^a UNIV LILLE   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANILIDE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); PYRROLE DERIVATIVE;

ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CATTLE; CYTOTOXICITY; DNA BINDING; DNA DRUG COMPLEX; DNA SEQUENCE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NONHUMAN; THYMUS;

ANILIDES; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CIRCULAR DICHROISM; DNA; DNA FOOTPRINTING; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; PYRROLES; TEMPERATURE;

BOS TAURUS;

EID: 0034689417     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00028-7     Document Type: Article

References (24)

1. Bailly C., Chaires J.B. Bioconjugate Chem. 9:1998;513.
2. Boykin D.W., Kumar A., Spychala J., Zhou M., Lombardi R.L., Wilson W.D., Dykstra C.C., Jones S.K., Hall J.E., Tidwell R.R., Laughton C., Nunn C.M., Neidle S. J. Med. Chem. 38:1995;912.
3. Boykin D.W., Kumar A., Xiao G., Wilson W.D., Bender B.C., McCurdy D.R., Hall J.E., Tidwell R.R. J. Med. Chem. 41:1998;124.
4. Wang H.-K., Morris-Natschke S.L., Lee K.-H. Med. Res. Rev. 17:1997;367.
5. Pommier Y., Pourquier P., Fan Y., Strumberg D. Biochim. Biophys. Acta. 1400:1998;83.
6. McHugh M.M., Woynarowski J.M., Sigmund R.D., Beerman T.A. Biochem. Pharmacol. 38:1989;2323.
7. Kim J.S., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E. J. Med. Chem. 39:1996;992.
8. Xu Z., Li T.-K., Kim J.S., LaVoie E., Breslauer K.J., Liu L.F., Pilch D.S. Biochemistry. 37:1998;3558.
9. 8.85) CHN.
10. Lee M., Coulter D.M., Lown J.W. J. Org. Chem. 53:1988;1855.
11. Bailly C., Pommery N., Houssin R., Hénichart J.P. J. Pharm. Sci. 78:1989;910.
12. Gallo-Rodriguez C., Ji X., Melman N., Siegman B.D., Sanders L.H., Orlina J., Fischer B., Pu Q., Olah M.E., van Galen P.J.M., Stiles G.L., Jacobson K.A. J. Med. Chem. 37:1994;636.
13. Tanaka K.-I., Yoshifuji S., Nitta Y. Chem. Pharm. Bull. 36:1988;3125.
14. Lown J.W., Krowicki K. J. Org. Chem. 50:1985;3774.
15. Hofmann K., Finn F.M., Kiso Y. J. Am. Chem. Soc. 100:1978;3585.
16. Bailly C., Michaux C., Colson P., Houssier C., Sun J.S., Garestier T., Hélène C., Hénichart J.P., Rivalle C., Bisagni E., Waring M.J. Biochemistry. 33:1994;15348.
17. Colson P., Bailly C., Houssier C. Biophys. Chem. 58:1996;125.
18. Portugal J., Waring M.J. Eur. J. Biochem. 167:1987;281.
19. Plouvier B., Bailly C., Houssin R., Rao K.E., Lown J.W., Hénichart J.P., Waring M.J. Nucleic Acids Res. 19:1991;5821.
20. Bailly C., Dassonneville L., Carrasco C., Lucas D., Kumar A., Boykin D.W., Wilson W.D. Anti-Cancer Drug Des. 14:1999;47.
21. 50 refers to the concentration reducing by 50% the optical density of treated cells versus untreated controls.
22. Pommier Y., Kohlhagen G., Bailly C., Waring M.J., Mazumder A., Kohn K.W. Biochemistry. 35:1996;13303.
23. Moore B.M., Seaman F.C., Hurley L.H. J. Am. Chem. Soc. 119:1997;5475.
24. Takebayashi Y., Pourquier P., Yoshida A., Kohlagen G., Pommier Y. Proc. Natl. Acad. Sci. USA. 96:1999;7196.